Scynexis

Trending Articles

  1. Scleroderma treatment by Certa Therapeutics granted US FDA fast track FT011 is a novel, first-in-class oral therapy for the treatment of chronic fibrosis in multiple organs
  2. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
  3. Indian government bans three medicines owing to health risks Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
  4. Dickson achieves ISO 14001 certification ISO 14001 certification highlights a companies' long-term efforts to manage its environmental impact
  5. The key role of IVDs in healthcare: challenges to commercialisation and access In simple terms, in vitro diagnostic (IVD) tests are done on samples such as blood or tissue that have been taken from the human body. IVDs can detect diseases, conditions and...

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

Related Content

Research & Development

Cypralis to acquire Scynexis assets

The deal includes a large portfolio of cyclophilin inhibitors
Research & Development

Dennis Schmatz joins Scynexis

Will provide advice to US firm as it advances drug development programme
Sustainability

Scynexis extends sleeping sickness collaboration to 2012

Extends collaboration with the Drugs for Neglected Diseases initiative (DNDi)
Subscribe now